belov artem , cfo

10
Belov Artem, CFO 123458, Moscow, Str. Twardowski, 8/1, office 405 Skype: artem.belov.msp phone : +7 (925) 859-10-85 [email protected]

Upload: livvy

Post on 07-Jan-2016

53 views

Category:

Documents


0 download

DESCRIPTION

Belov Artem , CFO. 123458, Moscow, Str. Twardowski, 8 / 1, office 405 Skype: artem.belov.msp phone : +7 ( 925 ) 859-10-85 [email protected]. The product. Known approach of cancer tissue diagnostic. 1. Number of tumor cells. 2. Intensity of staining. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Belov Artem , CFO

Belov Artem, CFO123458, Moscow, Str. Twardowski, 8/1, office 405Skype: artem.belov.mspphone : +7 (925) 859-10-85 [email protected]

Page 2: Belov Artem , CFO

The product

1. Number of tumor cells

2. Intensity of staining

Known approach of cancer tissue diagnostic

Our approach based on both known measurements +

Identify the number of antigens in each cell directly

(Efficiency is proved by Russian state pathologist burro)

Page 3: Belov Artem , CFO

Uniqueness

Microspace shows real distribution of

antigens in tumor cells

Analogues (Leica, Carl Zeiss) shows one rough parameter of antigens in

tumor cells Precise knowledge on antigens allows

development of much more efficient treatment plans

Score evaluation

+2

Antigens distribution

Page 4: Belov Artem , CFO

Microspace equipment use for developing the new approach

Market leadership through better efficiency of

cancer therapy

Page 5: Belov Artem , CFO

Microspace Team

• Experience in international projects• 30 years of medical experience• 20 years experience in development

Page 6: Belov Artem , CFO

Global market

Market size: - 190 ml. USD in 2012.- 150 thousands diagnostic systems.

Tripling of the market by 2020!

CAGR till 2018 – 23%.

Page 7: Belov Artem , CFO

Business model

Hardware – B2B segment for major DistributorSoftware – B2C, B2B segment

Advantages:-Great market potential of new approach-Unique technology and protectable IP

Page 8: Belov Artem , CFO

Main budget figures

2014 - $ 0.7 ml to launch the products in

Russia and patenting processes

Reaching breakeven point in the 2nd qr.

2015

2015 -2017 – Exit or next round for

scaling

Financials (K USD)

2014 2015 2016

Revenues 400 924 1,801

Costs 1,056 1,185 1,581

EBITDA -656 -261 220

Page 9: Belov Artem , CFO

Great opportunity of industrial take over within 2-4 yearsBy this time, Microspace will be:

- Leader of digital pathology in Russia- Pioneer of new technology wave in the global scaleMore than 10 comparable takeovers

Page 10: Belov Artem , CFO

THANK YOU FOR ATTENTION

123458, Moscow, Str. Twardowski, 8/1, office 405Skype: artem.belov.mspphone: +7 (925) [email protected]

Artem Belov, CFO